Innovative Medicines Canada (Medicaments novateurs Canada)
| Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
|---|---|---|
|
Advocate for the adoption of innovative payer agreements at the pan-Canadian level that would incorporate real world evidence
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Advocate for workload capacity building and the acceleration of the work of the pan-Canadian Pharmaceutical Alliance which is an intergovernmental collaboration currently chaired by BC
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Budget 2025 preparation and submission discussion.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Finances and Budgets, Health
|
|
Discussion on the Pharmaceutical Care Management Strategy
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Engage with the BC government to advocate for greater access to innovative medicines and vaccines for British Columbians, supportive policies to attract research and development investment, and greater collaboration to build a stronger life sciences sector and a more sustainable health system.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
COVID-19, Economic Development and Trade, Finances and Budgets, Government Procurement, Health, Industry
|
|
Introductory meeting, update on life sciences strategy, life sciences sector value to BC in health and economic recovery.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Finances and Budgets, Health
|
|
Introductory meeting – we spoke about IMC and our members value to BC in health and economic recovery.
|
Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation, Development of any legislative proposal by the government of British Columbia, a Provincial entity or a member of the Legislative Assembly, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Decision by the Executive Council or a member of the Executive Council to have the private sector instead of the Crown provide goods or services to the government of British Columbia or a Provincial entity, Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity, Decision by the Executive Council or a member of the Executive Council to transfer from the Crown for consideration all or part of, or any interest in or asset of, any business, enterprise or institution that provides goods or services to the Crown, a Provincial entity or the public, Introduction, amendment, passage or defeat of any Bill or resolution in or before the Legislative Assembly
|
Health
|
|
life sciences sector
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
PharmaCare budget, pharmaceutical listings and the Pharmaceutical Care Management Strategy
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|